
What is E-prescribing?
E-prescribing enables physicians to electronically send an accurate, error-free and understandable prescription directly to a pharmacy from the point-of-care, an element that the Centers for Medicare and Medicaid Services (CMS) says is integral to improving the quality of patient care.
E-prescribing technology includes on-line computerized tools to create and sign prescriptions, perform automated drug safety checks, identify formulary and prescription drug benefits and to help monitor patient medication adherence.
Title 1 of the Medicare Modernization Act of 2003 (MMA) requires drug plans participating in the prescription drug benefit (Part D) to support and comply with electronic prescribing standards. And while E-prescribing is optional for physicians and pharmacies those who choose to E-prescribe covered Part D drugs to enrolled Part D beneficiaries must comply with the E-prescribing standards.
What are the benefits of E-prescribing?
CMS says that E-prescribing can help prevent medication errors by electronically checking dosage, interactions with other medications and therapeutic duplication at the time of prescribing. CMS also believes that E prescribing can improve the quality of care, efficiency, and reduce costs by—
- Actively promoting appropriate drug usage, such as following a medication regimen for a specific condition.
- Providing information about formulary-based drug coverage, including formulary alternatives and co-pay information.
- Speeding up the process of renewing medications by reducing the number of phone calls.
- Providing instant connectivity between the health care provider, the pharmacy, health plans/PBMs, and other entities, improving the speed and accuracy of prescription dispensing, pharmacy callbacks, renewal requests, eligibility checks, and medication history.
Furthermore, CMS says E-prescribing will create efficiencies in the administration of the Part D drug benefit, by facilitating patient eligibility checks, promoting generic drugs and appropriate use, and creating timely interface with formularies. E-prescribing will also improve patient safety by preventing medication errors resulting from illegible handwriting on paper prescriptions.
Where can I read more about E-prescribing?
On November 7, 2005, the Medicare Program; E-prescribing and the Prescription Drug Program; Final Rule was published in the Federal Register. The foundation standards included in this rule applied to all electronic prescribing done under Part D of the MMA. CMS implemented pilot projects to test additional standards in 2006 and as a result of these pilot projects additional standards were published in the Medicare Program; Proposed Standards for E-prescribing Under Medicare Part D; Proposed Rule on November 16, 2007.
On April 7, 2008 the Medicare Program; Standards for E-prescribing Under Medicare Part D and Identification of Backward Compatible Version of Adopted Standard for E-prescribing and the Medicare Prescriptions Drug Program (Version 8.1); Final Rule was published in the Federal Register. The final rule adopts uniform standards for formulary and benefit transactions, medications history transactions, and fill status notifications and provides the following three electronic tools for use in E-prescribing:
- Formulary and benefit transactions: gives prescribers information about which drugs are covered by a Medicare beneficiary's prescription drug benefit plan.
- Medication history transactions: provides prescribers with information about medications a beneficiary is already taking, including those prescribed by other providers, to help reduce the number of adverse drug events.
- Fill Status notifications: allows prescribers to receive an electronic notice from the pharmacy telling them that a patient's prescription has been picked up, not picked up, or has been partially filled, to help monitor medication adherence in patients with chronic conditions.
In a July 21, 2008 Press Release CMS announced their latest effort to encourage physician adoption of E-prescribing by offering incentive payments to physicians and other eligible professionals who use the technology saying that E-prescribing is more efficient and convenient for consumers, improves the quality of care, lowers administrative costs and its widespread use would eliminate thousands of medication errors every year.
In the July press release CMS cites the July 2006 Institute of Medicine (IOM) report, Preventing Medical Errors which said that more than 1.5 million Americans are injured each year by drug errors many of which can be prevented through use of E-prescribing. The Department of Health and Human Services says they expect the use of the technology to save the program as much as $156 million over five years through avoided adverse drug events.

How will physicians be impacted?
Section 132 of the Medicare Improvements for Patients and Providers Act (MIPPA) of 2008 (H.R. 6331) authorizes CMS to pay an incentive bonus to physicians for successful E-prescribing beginning in 2009 and continuing through 2013.
For four years beginning in 2009 Medicare will provide incentive payments to eligible professionals who are deemed a successful electronic prescriber. MIPPA of 2008 identifies successful electronic prescribers as those who either report applicable electronic prescribing measures established under the Physician Quality Reporting Initiative (PQRI) or who electronically submit prescriptions under Medicare Part D at a sufficient level as determined by CMS.
Beginning in 2014, bonuses for e-prescribing will be phased out and physicians who haven't adopted E-prescribing will be penalized in the form of reduced Medicare payments. Physicians who have a legitimate reason for not complying may be granted an exception.
Eligible professionals who are successful E-prescribers will receive the following incentive payments:
For 2009 – 2%
For 2010 – 2%
For 2011 – 1%
For 2012 – 1%
For 2013 – 0.5%
Eligible professionals who are not successful E-prescribers face the following reductions in Medicare reimbursement:
For 2012 – 1%
For 2013 – 1.5%
For 2014 & each successive year – 2%
On October 6-7th in Boston, Massachusetts, CMS held a conference to educate physicians and other stakeholders on the new E-prescribing incentive program. The Medical Group Management Association (MGMA) a proponent of E-prescribing was a cosponsor of the conference. CMS defined the goals of the E-prescribing conference to include:
- Equip healthcare professionals and other stakeholders with the knowledge and the tools to integrate E-prescribing into their business model;
- Educate healthcare professionals about the structure and implementation of the incentive payment structure with respect to E-prescribing and PQRI;
- Generate discussion about the use of E-prescribing and other e-health initiatives to increase patient compliance and overall health outcomes;
- Identify and promote opportunities to overcome barriers to adoption of this new technology; and
- Address constituent concerns about privacy, security and risk management with respect to implementation of the E-prescribing incentive payment program.
What if state laws are in conflict with E-prescribing?
CMS reports that they have identified several categories of State laws that are preempted, in whole or in part, upon the effective date of the final rule, January 1, 2006. The following categories of State laws are unenforceable when they apply to covered Part D drugs that are electronically prescribed for Part D eligible individuals and restrict Medicare’s ability to carry out the e-prescribing program:
- State laws that expressly prohibit electronic prescribing.
- State laws that prohibit the transmission of electronic prescriptions through intermediaries, such as networks and switches or PBMs, or that prohibit access to such prescriptions by plans or their agents or other duly authorized third parties.
- State laws that require certain language to be used, such as dispense as written, to indicate whether generic drugs may or may not be substituted in so far as such language is not consistent with the adopted standards.
- State laws that require handwritten signatures or other handwriting on prescriptions.
CMS Exempts Physicians from DMEPOS Accreditation Requirement for now…
As reported in Volume 4, Issue 2 of the Oplinc Best Practices Review newsletter the Medicare Modernization Act (MMA) of 2003 established the DMEPOS Competitive Bidding Program and section 302(a) (1) of the MMA requires the Secretary to establish and implement quality standards for suppliers of certain items, including consumer service standards, to be applied by recognized independent accreditation organizations.
While physicians and treating practitioners were exempted from having to participate in the competitive bidding program when they provided certain DMEPOS to their own patients they were not exempt from the accreditation requirements.
Physicians and physician organizations have been advocating the physician exemption to the accreditation requirement as the process is time-consuming, expensive and current accreditation requirements are largely impractical for the very small number of items they dispense to their patients.
Physicians have obtained at least temporary relief from this regulatory burden as Section 154 DELAY IN AND REFORM OF MEDICARE DMEPOS COMPETITIVE ACQUISITION PROGRAM subsection F APPLICATION OF ACCREDITATION REQUIREMENT of the MIPPA contains language that allows CMS to exempt physicians from the DMEPOS accreditation requirement.
This exemption was confirmed by CMS during the September 3, 2008 Special Open Door Forum (ODF) to provide guidance to DMEPOS provider. However, CMS retains the right to establish accreditation standards for physicians in the future…
If you missed this Special Forum an audio recording will be posted to the Special Open Door Forum website at http://www.cms.hhs.gov/OpenDoorForums/05_ODF_SpecialODF.asp and will be accessible for downloading beginning September 10, 2008.
UnitedHealthcare’s Accreditation Requirement Delayed
On August 20, 2008 UnitedHealthcare published an update on their Web site announcing their decision to delay accreditation requirements for physicians and outpatient imaging sites that bill on a 1500 Health Insurance Claim Form or its electronic equivalent. These providers are required to apply to be accredited before being reimbursed for computed tomography, magnetic resonance imaging, positron emission tomography, nuclear medicine, nuclear cardiology, and echocardiography procedures.
Originally the accreditation requirement was to be effective in the third quarter 2008, but in their announcement UnitedHealthcare says the new requirement will not take effect until the fourth quarter of 2009.
Although the program has been delayed UnitedHealthcare advises providers not to delay in taking the necessary steps to become accredited.
UnitedHealthcare identifies diagnostic imaging accreditation programs as a key initiative to advance the quality and safety of imaging studies and emphasizes the need for consumers to receive services from facilities whose equipment, technologists and physicians are in compliance with established accreditation performance standards.
UnitedHealthcare identified the following key factors in their decision for delaying the program stating:
The recent implementation of the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA) requires providers of advanced imaging services to be accredited by Jan. 1, 2012. Effective this date, accreditation will become a mandatory requirement in order to receive payment for the technical component of imaging services. We believe it will be beneficial to our network providers to more closely align our reimbursement adjustment timeline with MIPPA.
While the growth in the number of accredited practices is impressive, we have also received feedback that some communities may not have a sufficient number of accredited facilities to meet patient and physician needs.
UnitedHealthcare recognizes the American College of Radiology (ACR) and the Intersocietal Accreditation Commission (IAC) standards. Specific accreditation guidelines and standards are available on the ACR and IAC Web sites:
American College of Radiology (ACR)
Acr.org
800.770.0145
Intersocietal Accreditation Commission (IAC)
Intersocietal.org
800. 838.2110
UnitedHealthcare provides the following chart containing the CPT codes that are included in the UnitedHealthcare Imaging Accreditation Program:
| CPT |
Description |
CT |
| 70450 |
CT, head or brain; without contrast material |
| 70460 |
CT Head/brain w/ contrast |
| 70470 |
CT Head/brain w/o & w/contrast |
| 70480 |
CT, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material |
| 70481 |
CT orbit w/contrast |
| 70482 |
CT orbit w/o & w/contrast |
| 70486 |
CT, maxillofacial area; without contrast material |
| 70487 |
CT Maxllfcl w/ contrast |
| 70488 |
CT Maxllfcl w/o & w/contrast |
| 70490 |
CT, soft tissue neck; without contrast material |
| 70491 |
CT Soft tissue neck w/contrast |
| 70492 |
CT Soft tissue neck w/o & w/ contrast |
| 70496 |
CT Angiography, head, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 70498 |
CT Angiography, neck, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 71250 |
CT, thorax; without contrast material |
| 71260 |
CT Thorax w/ contrast |
| 71270 |
CT Thorax w/o & w/ contrast |
| 71275 |
CT Angiography, chest (noncoronary), followed by with contrast material(s), including noncontrast images, if performed, and image post processing |
| 72125 |
CT, cervical spine; without contrast material |
| 72126 |
CT C Spine w/ contrast |
| 72127 |
CT C Spine w/o & w/contrast |
| 72128 |
CT, thoracic spine; without contrast material |
| 72129 |
CT T Spine w/ contrast |
| 72130 |
CT T Spine w/o & w/contrast |
| 72131 |
CT, lumbar spine; without contrast material |
| 72132 |
CT L Spine w/ contrast |
| 72133 |
CT L Spine w/o & w/contrast |
| 72191 |
CT Angiography, pelvis, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 72192 |
CT, pelvis; without contrast material |
| 72193 |
CT Pelvis w/contrast |
| 72194 |
CT Pelvis w/o & w/contrast |
| 72292 |
CT Guidance |
| 73200 |
CT, upper extremity; without contrast material |
| 73201 |
CT Upper extremity w/contrast |
| 73202 |
CT Upper extremity w/o & w/ contrast |
| 73206 |
CT Angiography, upper extremity, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 73700 |
CT, lower extremity; without contrast material |
| 73701 |
CT Lower extremity w/contrast |
| 73702 |
CT Lower extremity w/o & w/ contrast |
| 73706 |
CT Angiography, lower extremity, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 74150 |
CT, abdomen; without contrast material |
| 74160 |
CT Abdomen w/contrast |
| 74170 |
CT Abdomen w/o & w/contrast |
| 74175 |
CT Angiography, abdomen, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 76380 |
CT Limited or localized follow-up study |
| 76497 |
Unlisted CT Procedure |
| 77011 |
CT guidance for stereotactic localization |
| 77012 |
CT guidance for needle placement, radiological supervision and interpretation |
| 0145T |
CT, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image post processing; cardiac structure and morphology |
| 0146T |
CT, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image post processing; computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), without quantitative evaluation of coronary calcium |
| 0148T |
CT, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image post processing; cardiac structure and morphology and computed tomographic angiography of coronary arteries (including native and anomalous coronary arteries, coronary bypass grafts), without quantitative evaluation of coronary calcium |
| 0150T |
CT, heart, with contrast material(s), including noncontrast images, if performed, cardiac gating and 3D image post processing; cardiac structure and morphology in congenital heart disease |
MR |
| 70336 |
MR Imaging Temporomandibular Joint |
| 70540 |
MRI Face, orbit, neck w/o contrast |
| 70542 |
MRI Face, orbit, neck with contrast |
| 70543 |
MRI Face, orbit, neck w/& w/o contrast |
| 70544 |
MRA Head w/o contrast |
| 70545 |
MRA Head w/ contrast |
| 70546 |
MRA Head w/& w/o contrast |
| 70547 |
MRA Neck w/o contrast |
| 70548 |
MRA Neck w/ contrast |
| 70549 |
MRA Neck w/& w/o contrast |
| 70551 |
MRI Head w/o contrast |
| 70552 |
MRI Head w/contrast |
| 70553 |
MRI Head w/& w/o contrast |
| 71550 |
MRI Chest w/o contrast |
| 71551 |
MRI Chest w contrast |
| 71552 |
MRI Chest w & w/o contrast |
| 71555 |
MRA Chest (exc myocardium) w/or w/o contrast |
| 72141 |
MRI Cervical spine w/o contrast |
| 72142 |
MRI Cervical spine w/contrast |
| 72146 |
MRI Thoracic spine w/o contrast |
| 72147 |
MRI Thoracic spine w/contrast |
| 72148 |
MRI Lumbar spine w/o contrast |
| 72149 |
MRI Lumbar spine w/contrast |
| 72156 |
MRI C Spine w/& w/o contrast |
| 72157 |
MRI T Spine w/& w/o contrast |
| 72158 |
MRI L Spine w/& w/o contrast |
| 72159 |
MRA Spinal canal w/or w/o contrast |
| 72195 |
MRI Pelvis w/o contrast |
| 72196 |
MRI Pelvis w/ contrast |
| 72197 |
MRI Pelvis w/& w/o contrast |
| 72198 |
MRI Pelvis w or w/o contrast |
| 73218 |
MRI Upper extremity other than joint w/o contrast |
| 73219 |
MRI Upper extremity other than joint w contrast |
| 73220 |
MRI Upper extremity other than joint w/contrast & w/o |
| 73221 |
MRI Upper extremity joint w/o contrast |
| 73222 |
MRI Upper extremity joint w/contrast |
| 73223 |
MRI Upper extremity joint w/& w/o contrast |
| 73225 |
MRI Upper extremity, with or w/o contrast |
| 73718 |
MRI Lower extremity other than joint w/o contrast |
| 73719 |
MRI Lower extremity joint w/contrast |
| 73720 |
MRI Lower extremity other than joint w/contrast & w/o |
| 73721 |
MRI Lower extremity joint w/o contrast |
| 73722 |
MRI Lower extremity joint w/contrast |
| 73723 |
MRI Lower extremity joint w/& w/o contrast |
| 73725 |
MRA Lower extremity w/or w/o contrast |
| 74181 |
MRI Abdomen w/o contrast |
| 74182 |
MRI Abdomen w/contrast |
| 74183 |
MRI Abdomen w/& w/o contrast |
| 74185 |
MRA Abdomen w/or w/o contrast |
| 75557 |
Cardiac magnetic resonance imaging for morphology and function without contrast material |
| 75558 |
Cardiac magnetic resonance imaging for morphology and function without contrast material; with flow/velocity quantification |
| 75559 |
Cardiac magnetic resonance imaging for morphology and function without contrast material; with stress imaging |
| 75560 |
Cardiac magnetic resonance imaging for morphology and function without contrast material; with flow/velocity quantification and stress |
| 75561 |
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences |
| 75562 |
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with flow/velocity quantification |
| 75563 |
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with stress imaging |
| 75564 |
Cardiac magnetic resonance imaging for morphology and function without contrast material(s), followed by contrast material(s) and further sequences; with flow/velocity quantification and stress |
| 75635 |
CT angiography, abdominal aorta and bilateral iliofemoral lower extremity runoff, with contrast material(s), including noncontrast images, if performed, and image post processing |
| 76390 |
MRI Spectroscopy |
| 76498 |
Unlisted MRI Procedure |
| 77021 |
MRI Guidance for needle placement; Rad supervision & interpretation |
| 77022 |
Magnetic resonance guidance for, and monitoring of parenchymal tissue ablation |
| 77058 |
MRI Breast w/and/or w/o contrast unilateral |
| 77059 |
MRI Breast w/and/or w/o contrast Bilateral |
| 77084 |
MRI Imaging Bone Marrow Blood Supply |
| |
Nuclear Medicine |
| 78003 |
Thyroid suppress or stimulation |
| 78006 |
Thyroid uptake and scan |
| 78007 |
Thyroid, image, multiple uptakes |
| 78010 |
Thyroid scan only |
| 78011 |
Thyroid imaging with flow |
| 78015 |
Thyroid met imaging |
| 78016 |
Thyroid met imaging with additional studies |
| 78018 |
Thyroid scan whole body |
| 78020 |
Thyroid carcinoma metastases uptake |
| 78070 |
Parathyroid nuclear imaging |
| 78075 |
Adrenal nuclear imaging |
| 78099 |
Unlisted endocrine procedure, diagnostic nuclear medicine |
| 78102 |
Bone marrow imaging, limited |
| 78103 |
Bone marrow imaging, multiple |
| 78104 |
Bone marrow imaging, whole body |
| 78185 |
Spleen imaging w & w/o vascular flow |
| 78195 |
Lymph system imaging |
| 78199 |
Unlisted hematopoietic diagnostic nuclear medicine |
| 78201 |
Liver imaging |
| 78202 |
Liver imaging with flow |
| 78205 |
Liver imaging spect (3D) |
| 78206 |
Liver imaging spect w/ vascular flow |
| 78215 |
Liver & spleen imaging |
| 78216 |
Liver & spleen imaging with flow |
| 78220 |
Liver function study |
| 78223 |
HIDA Scan |
| 78230 |
Salivary gland imaging |
| 78231 |
Serial salivary gland |
| 78232 |
Salivary gland function exam |
| 78258 |
Esophagus motility study |
| 78261 |
Gastric mucosa imaging |
| 78262 |
Gastroesophageal reflux exam |
| 78264 |
Gastric emptying study |
| 78278 |
GI Bleeder scan |
| 78282 |
GI Protein exam |
| 78290 |
Meckel's diverticulum imaging |
| 78291 |
Leveen shunt patency exam |
| 78299 |
Unlisted gastrointestinal procedure |
| 78300 |
Bone or joint imaging ltd |
| 78305 |
Bone or joint imaging multiple |
| 78306 |
Bone scan whole body |
| 78315 |
Bone scan 3 phase study |
| 78320 |
Bone joint imaging tomo test |
| 78399 |
Unlisted musculoskeletal procedure |
| 78414 |
Non-imaging heart function |
| 78428 |
Cardiac shunt imaging |
| 78445 |
Radionuclide venogram non-cardiac |
| 78456 |
Acute venous thrombosis imaging, peptide |
| 78457 |
Venous thrombosis imaging unilateral |
| 78458 |
Venous thrombosis images, bilateral |
| 78459 |
Myocardial imaging, positron emission tomography (pet) metabolic eval. |
| 78460 |
Thallium scan rest only |
| 78461 |
Myocardial perf stress or rest multiple study |
| 78464 |
Heart image (3-D) single |
| 78465 |
Myocardial perf w/spect multiple |
| 78466 |
Myocardial infarction scan |
| 78468 |
Heart infarct image EF |
| 78469 |
Heart infarct image 3-D |
| 78472 |
Gated heart, resting |
| 78473 |
Cardiac blood pool muga scan |
| 78481 |
Heart first pass single |
| 78483 |
Cardiac blood pool imaging-multiple |
| 78491 |
Myocardial imaging, positron emission tomography (PET), perfusion; single study at rest or stress |
| 78492 |
Myocardial imaging, positron emission tomography (PET), perfusion; multiple studies at rest or stress |
| 78494 |
Cardiac blood pool imaging, spect |
| 78496 |
Cardiac Blood Pool Imaging - Single study @ rest (Use with 78472) |
| 78499 |
Unlisted cardiovascular nuclear exam |
| 78580 |
Pulmonary perfusion imaging |
| 78584 |
Pulmonary perfusion with vent single breath |
| 78585 |
Pulmonary perfusion w/breath washout, w or w/o single |
| 78586 |
Pulmonary ventilation imaging |
| 78587 |
Pulmonary ventilation multi |
| 78588 |
Pulmonary perfusion w/ventilation |
| 78591 |
Vent image 1 breath, 1 projection |
| 78593 |
Vent image 1 projection, gas |
| 78594 |
Vent image multi projection, gas |
| 78596 |
Lung differential function |
| 78599 |
Unlisted respiratory nuclear exam |
| 78600 |
Brain imaging, less than 4 static views |
| 78601 |
Brain imaging, less than 4 static views; with vascular flow |
| 78605 |
Brain imaging, minimum 4 static views |
| 78606 |
Brain imaging, minimum 4 static views; with vascular flow |
| 78607 |
Brain imaging, tomographic (SPECT) |
| 78608 |
Brain imaging, positron emission tomography (PET) metabolic evaluation |
| 78609 |
Brain imaging, positron emission tomography (PET) metabolic evaluation, perfusion evaluation |
| 78610 |
Brain flow imaging only |
| 78630 |
Cisternogram (cerebrospinal fluid flow) |
| 78635 |
Cerebrospinal ventriculography |
| 78645 |
CSF Shunt evaluation |
| 78647 |
Cerebrospinal fluid scan |
| 78650 |
CSF Leakage detection and localization |
| 78660 |
Radiopharmaceutical dacryocystography |
| 78699 |
Unlisted diagnostic nuclear med procedure |
| 78700 |
Kidney imaging (static) |
| 78701 |
Kidney imaging w/ vascular flow |
| 78707 |
Kidney imaging w/study vascular flow & function single |
| 78708 |
Kidney imaging single study w/pharm. intervention |
| 78709 |
Kidney imaging- multiple studies w & w/o pharm. intervention |
| 78710 |
Kidney imaging - tomographic (spect) |
| 78725 |
Kidney function study - non-imaging radioisotopic |
| 78730 |
Urinary bladder residual study |
| 78740 |
Ureteral reflux study |
| 78761 |
Testicular imaging w/vascular flow |
| 78799 |
Unlisted genitourinary procedure |
| 78800 |
Radiopharm localization of tumor or distribution of radiopharm agent(s), limited area |
| 78801 |
Radiopharm localization of tumor, multiple areas |
| 78802 |
Radiopharm localization of tumor, whole body, single day imaging |
| 78803 |
Radiopharm localization of tumor tomographic(spect) |
| 78804 |
Radiopharm localization of tumor or distribution of radiopharm agent(s); whole body, requiring two or more days imaging |
| 78805 |
Radiopharm localization of abscess, limited area |
| 78806 |
Radiopharm localization of abscess, whole body |
| 78807 |
Radiopharm localization of abscess, tomographic spect |
PET |
| 78811 |
Positron emission tomography (PET) imaging; limited area (eg, chest, head/neck) |
| 78812 |
Positron emission tomography (PET) imaging; skull base to mid-thigh |
| 78813 |
Positron emission tomography (PET) imaging; whole body |
| 78814 |
Positron emission tomography (PET) with concurrently acquired CT (CT) for attenuation correction and anatomical localization imaging; limited area (eg, chest, head/neck) |
| 78815 |
Positron emission tomography (PET) with concurrently acquired CT (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh |
| 78816 |
Positron emission tomography (PET) with concurrently acquired CT (CT) for attenuation correction and anatomical localization imaging; whole body |
Echocardiography |
| 93303 |
Transthoracic Echocardiography for Congenital Cardiac Anomalies; Complete |
| 93304 |
Transthoracic Echocardiology; Follow-up or Limited Study |
| 93307 |
Echocardiography, Transthoracic, Real-Time w/Image Documentation w/or w/o M-mode recording; complete |
| 93308 |
Echocardiography, Transthoracic, Real-Time w/Image Documentation w/or w/o M-mode recording; Follow-up or Limited Study |
| 93312 |
Echocardiography, Transesophageal, Real-Time with Image Documentation (2D) w/&w/o M-mode recording; including probe placement, image acquisition, interpretation and report |
| 93313 |
Echocardiography, Transesophageal, Real-Time with Image Documentation (2D) w/&w/o M-mode recording; including probe placement only |
| 93314 |
Image Acquisition, Interpretation and report only |
| 93315 |
Transesophageal Echocardiography for Congenital Cardiac Anomalies; including probe placement, image acquisition, interpretation and report |
| 93316 |
Transesophageal Echocardiography for Congenital Cardiac Anomalies; including probe placement only |
| 93317 |
Image Acquisition, Interpretation and report only |
| 93318 |
Echocardiography, transesophageal for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to continuous assessment of cardiac pumping function and to therapeutic measures on an immediate time bases |
| 93320 |
Doppler Echcontinuous ocardiography, pulsed waved &/or wave with spectral display; complete |
| 93321 |
Doppler Echocardiography, pulsed waved &/or continuous wave with spectral display; Follow-up or Limited Study |
| 93350 |
Echocardiography, transthoracic, real-time w/image documentation during rest & cardiovascular stress test using treadmill, bicycle or pharmacologically induced stress, w/interpretation & report. |
Source: www.unitedhealthcareonline.com |

The Medicare Improvements for Patients & Providers Act
When Congress overrode the President's veto of H.R. 6331 on July 15, 2008, the "Medicare Improvements for Patients and Providers Act of 2008” (MIPPA) became law. MIPPA retroactively rescinds a 10.6% cut in Medicare physician payments that went into effect July 1, 2008. While the retroactive rescission of physician payments was met with a collective sigh of relief by all, it must be understood that this is just a temporary fix to the physician payment system which remains to be addressed.
MIPPA provides a 0.5% update extension through December 2008 and a 1.1% update for 2009. MIPPA’s 18-month reprieve expires at the end of 2009 and unless Congress acts to prevent it the conversion factor is to be reduced by an estimated 21% on January 1, 2010.
While the temporary fix to physician payments was the cornerstone of MIPPA the bill also contains many other provisions affecting Medicare and Medicaid policy. Below is a brief summary of some of the more significant provisions:
| • |
Maintains physician payment rates for 2008 and provides a 1.1% increase for 2009 as described above; |
| • |
Extends the Physician Quality Reporting Initiative (PQRI) through 2010, increases incentive payments for reporting by 2%, and makes other changes to the program; |
| • |
Provides incentive payments for electronic prescribing (E-prescribing) for prescribers using qualified E-prescribing systems in 2009-2013. Beginning in 2011 payments will be reduced by 2% for prescribers who fail to e-prescribe beginning in 2011 (see The New E-Prescribing Incentive Program in this newsletter); |
| • |
Requires certain advanced imaging providers to be accredited by 2012; |
| • |
Delays and reforms the durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) Competitive Bidding program terminating contracts awarded under round one and setting the rebid date for 2009 and bidding for round two in 2011. The delay will be financed by cutting fee schedule payments for all items covered by round one bidding by 9.5% nationwide beginning January 1, 2009, followed by a 2% increase (with certain exceptions) in 2014; |
| • |
Allows for an exemption from the DME accreditation standards for health professionals including physicians until CMS has specific guidelines for health professionals or determines that quality standards apply to these health professionals; |
| • |
Extends the 1.0 floor to the geographic practice cost index (GPCI) on the physician work relative value unit (RVU) for 18 months; |
| • |
Requires that the budget neutrality adjustment be applied to the conversion factor and not to the physician work RVUs in 2009; |
| • |
Repeals the competitive bidding demonstration project for clinical laboratory services and reduces the fee schedule update for clinical lab services by 0.5% in each of the next 5 years; |
| • |
Extends the use of the cost to charge payment methodology under OPPS for brachytherapy and therapeutic radiopharmaceuticals through January 1, 2010, retroactive to July 1, 2008; |
| • |
Requires most (PFFS) Medicare plans to establish contracted provider networks for both individual and employer-group products starting in 2010, will no longer allow “deeming” to access providers; |
| • |
Delays the adoption of Medicaid payment based on average manufacturer price (AMP) for multiple source drugs to retail pharmacies through September 2009 and delays publication of AMP data until October 1, 2009. The National Community Pharmacy Association has stated that the move to payment based on AMP for multi-source drugs would result in reimbursement of 36%, on average, below acquisition cost for every generic prescription. |
What does the BNA Change Mean?
The Omnibus Budget Reconciliation Act of 1989 requires that increases or decreases in RVUs for a year that result in a change of more than $20 million from what the Medicare expenditures would have been without the changes must be adjusted to ensure budget neutrality.
The 2005 Five Year-Review of Current Procedural Terminology codes resulted in significant increases to the physician work RVUs (RVUs) for many of the most commonly performed Evaluation and Management (E&M) service codes. In order to maintain budget neutrality (BN) CMS applied a -10.1% work RVU adjustment to the 2007 Physician Fee Schedule and an additional -1.7% work RVU adjustment to the 2008 Physician Fee Schedule. This budget neutrality adjustment was applied to the work RVU of all services paid under the Medicare Physician Fee Schedule (labs and drugs were not affected as they are paid under separate fee schedules).
The application of the BN Adjuster to the work RVUs was not well-received. Traditionally CMS has applied the budget neutral adjustment to the conversion factor and the American Medical Association (AMA) and numerous other physician organizations advocated a return to the BN adjustment to the conversion factor. There are several reasons this approach was preferred:
| 1. |
When the BN adjustment is applied to work RVUs they disproportionately impact services that involve more physician work while a conversion factor adjustment would consistently impact all services in the physician fee schedule. |
| 2. |
Some payers utilizing the Medicare fee schedule have also adopted the use of the Budget Neutrality Work Adjuster (BNWA). Because the use of the BNWA reduces the total RVU even if the health plan offers an increase in the conversion factor it may still result in a reimbursement decrease. |
The MIPPA contained a provision changing how this Budget Neutrality Adjuster is applied, effective January 1, 2009 the BNA that resulted from the 2005 Five Year - Review will be applied to the conversion factor, rather than the work RVUs.
CONTACT US
Risë Marie Cleland
Rise@Oplinc.com
Oplinc, Inc.
315 W. Mill Plain Blvd.,
Suite 204
Vancouver, WA 98660
360.695.1608 office
360.695.6937 fax
www.Oplinc.com
Rise@Oplinc.com
UPCOMING ISSUE
Comments and suggestions for future issues are welcome, please forward correspondence to Risë Marie Cleland by email at: Rise@Oplinc.com
NEWSLETTER ARCHIVES
Volume 4 Issue 3
Volume 4 Issue 2
Volume 4 Issue 1
Volume 3 Issue 8
Volume 3 Issue 7
Volume 3 Issue 6
Volume 3 Issue 5
Volume 3 Issue 4
Volume 3 Issue 3
Volume 3 Issue 2
Volume 3 Issue 1
Volume 2 Issue 7
Volume 2 Issue 6
Resource Guide Issue 5
Volume 2 Issue 4
Volume 2 Issue 3
Volume 2 Issue 2
Volume 2 Issue 1
ABOUT THE EDITOR
Risë Marie Cleland is the founder and President of Oplinc, Inc., a national organization of oncology professionals. Through Oplinc, Inc. Ms. Cleland publishes the weekly Oplinc Fax Tracts focusing on the timely dissemination of information pertaining to billing, reimbursement and practice management in the oncology office and Oplinc’s Best Practices Review, which provides a more in-depth look at the issues and challenges facing oncology practices. Ms. Cleland also works as a consultant and advisor for physician practices, pharmaceutical companies and distributors.
IMPORTANT NOTICES
Please note that this newsletter is presented for informational purposes
only. It is not intended to provide coding, billing or legal advice. Regulations
and policies concerning Medicare reimbursement are a rapidly changing
area of the law. While we have made every effort to be current as of the
issue date, the information may not be as current or
comprehensive when you review it. Please consult with your legal counsel
for any specific reimbursement information. For Medicare regulations visit: www.cms.hhs.gov.
CPT® is a Trademark of the American Medical Association Current Procedural Terminology (CPT) is copyright 2007 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values, or related listings are included in CPT. The AMA assumes no liability for the data contained herein. |
 |